SIRT5 and breast carcinoma: Furthermore, treatment with compound 6 (50 μM) led to a rise in succinylated proteins in both mouse myoblasts (C2C12) and human breast cancer cells (MDA-MB-231) due to the suppression of SIRT5 desuccinylase activity [69].